Abstract-Extending safe, effective glycemic control to the general wards requires a simple approach using subcutaneous (SC) insulin. However, this approach can increase relative risk compared to intravenous insulin due to the increased variability of SC insulin appearance. This paper evaluates the accuracy of a SC plasma insulin model and optimizes its parameters using measured plasma insulin data from 6 less acute critical care patients treated with SC insulin. [6] [7] [8] [9] [10] . However, they are not suitable for less acute wards because of the demands they place on clinical staff [11] [12] [13] [14] and the lack of intravenous (IV) lines for IV delivery.
I. INTRODUCTION
Stress-induced hyperglycaemia is prevalent in critical care, and can occur in patients with no history of diabetes [1] [2] [3] [4] . Hyperglycaemia worsens outcomes, leading to further risk of complications, including sepsis [5] , myocardial infarction [1] , polyneuropathy, and multiple organ failure [2] . Adaptive model-based protocols for accurate glycaemic control (AGC) that modulate insulin and nutrition have shown considerable promise in the intensive care unit (ICU) [6] [7] [8] [9] [10] . However, they are not suitable for less acute wards because of the demands they place on clinical staff [11] [12] [13] [14] and the lack of intravenous (IV) lines for IV delivery.
To extend safe, effective glycaemic control to the general wards, a simple approach using subcutaneous (SC) insulin delivery is necessary. However, there is an increased rick when using SC insulin as its appearance is much more variable than IV insulin appearance [15] . This increased variability compounds the existing difficulty of managing intra-and inter-patient variability.
In model-based control, plasma insulin dynamics have a significant impact of identified model parameters, such as insulin sensitivity (SI). Hence, reducing error in modelling plasma insulin appearance will reduce SI variability and error, and thus increase the accuracy and utility of the parameter for glycaemic control. This paper evaluates the accuracy of a SC plasma insulin model and optimises model parameters for less acute critical care patients. Plasma insulin blood samples from an ongoing study of SC insulin delivery, in the Christchurch Hospital Intensive Care Unit (ICU) were used to evaluate this model.
II. PATIENTS AND METHODS

A. Subcutaneous Insulin Study Patients
A total of 6 patients enrolled in a prospective clinical trial studying a protocol for SC insulin delivery. Each patient had a set of blood samples assayed for insulin and C-peptide. Patients were included in the study if they were:
 Age ≥ 18 years  Expected to survive ICU care  Expected ICU length of stay ≥ 72hrs  Receiving treatment by the tablet-based STAR AGC protocol (Stochastic TARgeted) (2 sequential BG measurements ≥ 8mmol/L) [16] In a stable condition, likely to be discharged to less acute wards <48hrs Patients received 3 doses of SC insulin over 12 hours. Blood glucose (BG) was measured every 30 mins with a blood gas analyser (BGA, Radiometer ABL90Flex, Copenhagen). Insulin and nutrition doses were determined every 4 hours by an SC insulin protocol. This study was approved by the Upper South Regional Ethics Committee, New Zealand.
During each 12 hour trial, 18 blood samples were taken to assess plasma insulin concentrations. Samples were taken at times t = 0, 30, 60, 90, 180, 240mins where t = 0 mins marks the first SC insulin bolus given. Insulin concentrations were determined using immunometric assays (Elecsys 2010, Roche Diagnostics, Germany). The reported coefficient of variation (CV A ) for the insulin 3.8% [17, 18] . [19] . For forward simulation using regular SC insulin (e.g. Actrapid, Novo Nordisk, Denmark), an additional kinetics sub-model was added, modelling transport from the SC layer to the plasma [20] .
Accuracy and Optimization of a Subcutaneous Insulin Model for
Equation (1) Equation (2) Equation (3) Equation (4) Where x h , are the total insulin mass in the hexameric (h), local interstitial, (i), and dimeric or monomeric, (dm), compartments, respectively [ ], where the unique scaling factor, f RI , highlights the many currently unquantified processes at work during the absorption process. The parameters in Table II were identified using published clinical data to describe a typical plasma insulin profile for regular insulin [21] . The overall model describes the appearance a common of SC insulin type e.g. Actrapid (Novo Nordisk, Denmark). 
Residual Error =I(t) measured -I(t) modelled
Equation (5) where I(t) measured is the plasma insulin measured during the 12 hour trials and I(t) modelled is the forward prediction of the plasma insulin using the model identified SI profile for these patients during the 12 hour trials. Residuals were first calculated using the model parameters outlined above. The root mean square (RMS) and the median and interquartile range (IQR) of the residual errors was calculated for each patient and the overall cohort. Finally, an optimal value of the parameter, f RI was identified by iteratively searching the range of 0.60 to 0.20 in steps of 0.01 to find the value of f RI that generated the smallest residuals and the best model fit.
III. RESULTS AND DISCUSSION
A. SC Plasma Insulin Model
The SC plasma insulin model as published by Fisk [20] with f RI = 0.597 captures the dynamics of the regular SC insulin used in this study well, as seen in Figure I . This result indicates the underlying model structure for regular insulin is correct. However, there appears to be a positive bias leading to an overall median [IQR] residual error of -28.3 [-37 -19] mU/L. All 6 patients demonstrated this bias with the modelled insulin being consistently higher than the measured insulin as seen in Table III The original model value for f RI was found using data from 18 heathy male volunteers [20] . This change in f RI thus reflects a distinct difference in SC insulin kinetics between healthy volunteers and critical care patients. This parameter is equivalent to a unique clearance in the local interstitium. It lumps together difficult to quantify dynamics, such as clearance from the subcutaneous depot, affinity to antibodies (appearing as different volumes of distribution), and altered clearance routes. Therefore, the reduction of f RI suggests less of the injected SC insulin is appearing in critical care patients than would appear in a healthy individuals injected with the same SC insulin bolus.
This increased degradation of insulin in the local interstitium is likely to be due to the increased edema typical of critical care patients. The extra fluid at the injection site would slow the transport of insulin to the plasma, as well as allowing more insulin to be cleared via other pathways. In addition, the lack of movement and low skin temperatures found in the critically ill have been shown to slow the transport of insulin to the plasma [15, 22] . The air temperature in the Christchurch ICU is a constant 16 degrees Celsius, and most patients are immobilized and only wearing hospital gowns, both of which are typical in this setting.
Patient condition also affects the glucose-insulin metabolism resulting in inter-and intra-patient variability as condition evolves [23] . This impact is evident in Figure I , where there are a wide range of plasma insulin response curves. For example, Patient 6 shows an acute spike in plasma insulin after the 3 rd bolus while Patient 5 shows slow insulin plasma clearance resulting in plasma insulin concentration building up over time. Hence to extend safe, effective glycemic control to the general wards, a simple approach using subcutaneous (SC) insulin delivery and a simple, generalizable SC insulin kinetic transport model are necessary. Such a model must also have the ability to account a range of patient conditions. The ability to separately account for the variability of SC insulin kinetics would enable similar, proven models and methods used for AGC in critical care with IV insulin delivery to be used for SC insulin delivery, with the addition of an SC insulin model that meets these criteria.
To achieve this latter outcome, f RI needs to be optimized over large range of patient data instead of having patient specific insulin clearance parameters. Variability can also be managed through conservative insulin dosing and robust protocols. However, the distinct inter-cohort variation seen in this data highlights the importance to of understanding how the SC dynamics may be affected by the cohort, and accounting for them directly. In addition, SC insulin models based on healthy, T2DM or critical care data should only be cautiously applied to different cohorts. To extend safe, effective glycemic control to the general wards, a simple approach using subcutaneous (SC) insulin delivery is necessary. However, these changes increase the risk due to variability of the patient and the variability that can occur in SC insulin appearance [15] . The SC plasma insulin model evaluated captures the dynamics of the regular SC insulin well. However, there appears to be a positive bias leading to an overall median [IQR] residual error of -28.3 [-37 -19 ] mU/L. The optimized model reduced the RMS residual error by between 20% and 70% for each patient. The distinct inter-and intra-patient and cohort variation seen in this data highlights the importance of understanding how SC dynamics may be affected by the subject condition, and accounting for this variability directly in the SC model to better generalize existing proven metabolic models used in critical care environments.
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